MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
2.550
+0.040
+1.59%
After Hours: 2.600 +0.05 +1.96% 19:26 03/01 EST
OPEN
2.520
PREV CLOSE
2.510
HIGH
2.560
LOW
2.450
VOLUME
2.98M
TURNOVER
0
52 WEEK HIGH
6.75
52 WEEK LOW
0.7000
MARKET CAP
471.88M
P/E (TTM)
-1.0774
1D
5D
1M
3M
1Y
5Y
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
NASDAQ · 2d ago
A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Seeking Alpha · 4d ago
HC Wainwright & Co. Maintains Buy on Esperion Therapeutics, Lowers Price Target to $16
Benzinga · 4d ago
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
NASDAQ · 4d ago
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR), Beam Therapeutics (BEAM) and Opko Health (OPK)
TipRanks · 4d ago
Esperion’s Market Position and Outlook: A Hold Rating with a Revised Price Objective
TipRanks · 4d ago
Biotech Stocks Facing FDA Decision In March 2024
NASDAQ · 4d ago
Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target
Benzinga · 5d ago
More
About ESPR
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.